STOCK TITAN

United Therapeutics Corp. Stock Price, News & Analysis

UTHR Nasdaq

Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.

United Therapeutics Corporation (UTHR) delivers innovative therapies for pulmonary arterial hypertension and rare diseases through cutting-edge research and targeted drug development. This news hub provides investors, healthcare professionals, and stakeholders with timely updates on regulatory milestones, clinical trial progress, and strategic initiatives shaping the biopharmaceutical landscape.

Access verified press releases, financial disclosures, and scientific advancements in one centralized location. Our curated collection features updates on treprostinil-based treatments, FDA approvals, partnership announcements, and R&D pipeline developments – all essential for tracking UTHR's progress in addressing unmet medical needs.

Discover comprehensive coverage spanning earnings reports, manufacturing expansions, and therapeutic innovations. Content is rigorously vetted to ensure accuracy and relevance for both expert analysts and general readers seeking reliable information about this biotechnology leader.

Bookmark this page for streamlined access to United Therapeutics' latest developments. Check back regularly to stay informed about critical updates impacting patient care and investment considerations in the specialized pharmaceutical sector.

Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR) announced the full enrollment of the TETON 2 study, evaluating Tyvaso® (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF). The study enrolled 597 patients outside the U.S. and Canada and is part of a global program assessing inhaled treprostinil in IPF and progressive pulmonary fibrosis (PPF). Top-line data is expected in the second half of 2025. The TETON program is inspired by favorable outcomes from the INCREASE study, which showed significant improvements in forced vital capacity (FVC) for IPF patients using nebulized Tyvaso. United Therapeutics aims to use these studies to seek FDA approval for Tyvaso DPI to treat IPF and PPF.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
none
-
Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR) has elected Jan Malcolm, former Minnesota Commissioner of Health, to its Board of Directors. She was elected by shareholders during the annual meeting on June 26, 2024. Malcolm has a distinguished career in health policy, public health, and healthcare finance, highlighted by her leadership during the COVID-19 pandemic in Minnesota and her recognition by the American Medical Association with the AMA Award for Outstanding Government Service. Her experience includes roles at Allina Health and Courage Center. Malcolm will contribute to United Therapeutics' mission to address unmet medical needs, particularly in the area of end-stage organ diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
management
-
Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR) will present at the Goldman Sachs 45th Annual Global Healthcare Conference. Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session. This session is scheduled for Wednesday, June 12, 2024, from 4:00 p.m. to 4:35 p.m. Eastern Daylight Time in Miami Beach, Florida. The session will be accessible via a live webcast on United Therapeutics' website and will be archived for 90 days post-event. United Therapeutics, a public benefit , focuses on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
conferences
Rhea-AI Summary

United Therapeutics reported strong financial results for the first quarter of 2024, with total revenues growing by 34 percent year-over-year to $677.7 million. The company's net income also increased by 27 percent, demonstrating its solid commercial foundation and growth potential. Key highlights include the implementation of a $1 billion accelerated share repurchase program, showcasing confidence in the company's future prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.88%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
buybacks

FAQ

What is the current stock price of United Therapeutics (UTHR)?

The current stock price of United Therapeutics (UTHR) is $400.52 as of September 5, 2025.

What is the market cap of United Therapeutics (UTHR)?

The market cap of United Therapeutics (UTHR) is approximately 17.2B.
United Therapeutics Corp.

Nasdaq:UTHR

UTHR Rankings

UTHR Stock Data

17.21B
44.43M
1.77%
99.56%
3.47%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING